Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors clinical trials

Explore recruiting unresectable locally advanced or metastatic renal cell carcinoma with a clear cell component who progressed after 1st line treatment with checkpoint inhibitors clinical trials.

Also recruiting in Europe

Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors trials by city

Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Toronto Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Vancouver Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Montreal Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Calgary Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Edmonton Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Ottawa Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Winnipeg Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Quebec City Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Hamilton Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Kitchener Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in London Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Halifax Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in New York Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Los Angeles Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Chicago Unresectable Locally Advanced Or Metastatic Renal Cell Carcinoma With A Clear Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease